<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hypertension in patients on dialysis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hypertension in patients on dialysis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hypertension in patients on dialysis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rajiv Agarwal, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steve J Schwab, MD, FACP, FASN</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George L Bakris, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hypertension is common among patients on dialysis [<a href="#rid1">1</a>]. This topic reviews the epidemiology, pathogenesis, and treatment of hypertension in patients on dialysis.</p><p>Hypertension among patients with acute or chronic kidney disease who are not on dialysis is discussed elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3872.html" rel="external">"Overview of hypertension in acute and chronic kidney disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a>.)</p><p></p><p>Hypertension in the general adult population is discussed elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3852.html" rel="external">"Overview of hypertension in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3869.html" rel="external">"Choice of drug therapy in primary (essential) hypertension"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence</strong> – Hypertension is a common finding in patients on dialysis. Prevalence estimates vary widely among studies because of differences in the definition of hypertension and in methods of measuring blood pressure (BP; ie, either before and after hemodialysis or using ambulatory BP recordings). Based upon multiple studies, over 50 to 60 percent of patients on hemodialysis (up to 85 percent in some reports) and nearly 30 percent of patients on peritoneal dialysis are hypertensive [<a href="#rid2">2-6</a>]. In one multicenter trial that included 2535 adult patients on hemodialysis, the prevalence of hypertension, defined as one-week average predialysis systolic BP measurements of 150 mmHg or diastolic BP of 85 mmHg or the use of antihypertensive medications, was 86 percent [<a href="#rid5">5,6</a>].</p><p></p><p class="bulletIndent1">Hypertension is more common among patients who are just initiating dialysis (greater than 80 percent) because almost all such patients are volume overloaded [<a href="#rid7">7</a>]. Persistent hypertension often reflects inadequate volume control despite the initiation of dialysis [<a href="#rid4">4,8</a>]. (See <a class="local">'Pathogenesis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>BP and mortality</strong> – Multiple large observational studies have demonstrated a U-shaped relationship between BP and mortality among patients on dialysis [<a href="#rid9">9-22</a>]. This U-shaped relationship suggests that both low and high BPs are associated with a higher mortality compared with mid-range BPs. However, much of the BP and mortality data in patients on hemodialysis are complicated by the use of in-center dialysis unit pre- and postdialysis BP values; BPs recorded on an interdialytic day are monotonically associated with mortality [<a href="#rid23">23</a>].</p><p></p><p class="headingAnchor" id="H4"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Volume expansion is the major cause of hypertension in patients on dialysis [<a href="#rid24">24,25</a>]. Volume overload leads to an elevation in blood pressure (BP) via the combination of a rise in cardiac output and high systemic vascular resistance [<a href="#rid7">7,26</a>]. The role of volume expansion is supported by studies that have shown improvement in BP with volume reduction [<a href="#rid27">27-29</a>].</p><p>The removal of the excess sodium and reduction in target dry weight can result in the normalization of BP in &gt;60 percent of patients on hemodialysis and in many patients on peritoneal dialysis [<a href="#rid7">7,27,30-35</a>].</p><p>Sympathetic overactivity, activation of the renin-angiotensin system, and arteriosclerosis also contribute to hypertension in patients on hemodialysis [<a href="#rid36">36-38</a>].</p><p>Other potential contributors include changes in endothelium-derived vasoactive peptides [<a href="#rid39">39-42</a>], increases in intracellular calcium [<a href="#rid43">43,44</a>], and decreases in renalase [<a href="#rid45">45</a>]. Renalase is a catecholamine-metabolizing enzyme released by the kidney in response to catecholamine surge.</p><p>Elevated BP may also be associated with use of erythropoiesis-stimulating agents, over-the counter drugs such as nasal decongestants and nonsteroidal anti-inflammatory drugs (NSAIDs), illicit drugs such as cocaine, and herbal remedies such as ma huang and St. John's wort [<a href="#rid7">7,26,46,47</a>]. (See  <a class="medical medical_review" href="/d/html/3852.html" rel="external">"Overview of hypertension in adults", section on 'Primary hypertension'</a>.)</p><p class="headingAnchor" id="H508184876"><span class="h1">MONITORING AND DIAGNOSIS</span><span class="headingEndMark"> — </span>Ambulatory blood pressure monitoring (ABPM) is considered the gold standard for the diagnosis of hypertension [<a href="#rid48">48</a>]. Although ABPM provides reproducible readings and correlates with outcomes among patients on dialysis [<a href="#rid49">49-51</a>], ABPM is generally not used clinically, as it is cumbersome and poorly suited to day-to-day management of hypertension.</p><p>Our approach to monitoring blood pressure (BP) in patients with end-stage kidney disease varies according to dialysis modality:</p><p class="headingAnchor" id="H4096532"><span class="h2">Hemodialysis</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preferred BP measurement strategy</strong> – For patients on hemodialysis, we use self-recorded home BPs to monitor BP and diagnose hypertension. To preserve dialysis access, we instruct patients with an upper extremity arteriovenous fistula or graft to obtain home BPs from the contralateral arm. We instruct patients on conventional thrice weekly hemodialysis to check home BP readings twice daily for four days after the midweek dialysis treatment and to provide the measurements for averaging and review. Ideally, home BPs should not be checked in the immediate peridialytic period; for example, a patient dialyzed Wednesday morning should start checking home BPs Wednesday late afternoon or evening, whereas a patient dialyzed Wednesday afternoon or evening should start checking home BPs Thursday morning. Although the optimal frequency of monitoring is not known, we suggest home BP monitoring at monthly intervals [<a href="#rid52">52-54</a>]. Self-recorded home BP readings are efficient, accurate, and correlate with ABPM [<a href="#rid49">49,52,55,56</a>] and with outcomes [<a href="#rid9">9,10,23,57</a>]. The preferred technique of self-measured BP measurement is detailed elsewhere. (See  <a class="medical medical_review" href="/d/html/3820.html" rel="external">"Out-of-office blood pressure measurement: Ambulatory and self-measured blood pressure monitoring", section on 'Self-measured blood pressure (SMBP)'</a>.)</p><p></p><p class="bulletIndent1">If ABPM is used to confirm home-recorded BP readings, it is started after the midweek dialysis treatment and continued over the 44-hour interdialytic period to account for volume-related increases in BP [<a href="#rid49">49,55</a>]. ABPM generally shows a linear increase in BP as volume accrues.</p><p></p><p class="bulletIndent1">We do not use in-center dialysis unit pre- and postdialysis BP measurements to diagnose hypertension or titrate antihypertensive therapy. Although BP is closely monitored throughout the dialysis treatment to assess the hemodynamic stability of the patient during the treatment, the pre- or postdialysis BP readings correlate only weakly with ABPM. They associate inversely with clinical outcomes, which is counterintuitive [<a href="#rid11">11,12</a>]. Predialysis BP readings tend to overestimate and postdialysis readings underestimate BP readings obtained by ABPM, and the degree of bias is variable. In one systematic review of studies, compared with 44-hour ABPM, predialysis systolic BP was variably 42 mmHg higher or 25 mmHg lower, and postdialysis systolic BP was 33 mmHg higher to 36 mmHg lower [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1">In contrast to in-center pre- and postdialysis readings, BP readings obtained outside the dialysis unit (either by ABPM or self-recorded home measurement) are directly related to all-cause mortality [<a href="#rid9">9,10,23,57</a>]. As an example, a 2015 study showed that a single recording of systolic BP measured outside the dialysis unit was directly related to mortality (hazard ratio [HR] 1.26, 95% CI 1.14-1.40) for every 10 mmHg increase [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternate BP measurement strategy</strong> – If home BP monitoring is not possible or is unavailable, as a last resort, we use midweek median intradialytic systolic BP. As an example, in a patient who dialyzes Monday-Wednesday-Friday, if the median intradialytic systolic BP is 146 mmHg on Wednesday, the patient is very likely to be hypertensive. In one study, the midweek median intradialytic BP of 140 mmHg was approximately 80 percent sensitive and approximately 80 percent specific in diagnosing hypertension among patients on dialysis. For median diastolic BP of 80 mmHg, the sensitivity and specificity for diagnosing hypertension in the interdialytic period was approximately 75 percent each [<a href="#rid59">59</a>]. Furthermore, median intradialytic BP can track changes evoked by probing dry weight in these patients [<a href="#rid60">60</a>]. Nonetheless, the clinical use of median intradialytic systolic BP is suboptimal since it has wide limits of agreement with 44-hour ambulatory systolic BP, ranging from 16 to 20 mmHg.</p><p></p><p class="headingAnchor" id="H2351517757"><span class="h2">Peritoneal dialysis</span><span class="headingEndMark"> — </span>For patients on peritoneal dialysis, we use self-recorded home BPs to monitor BP and diagnose hypertension. We instruct patients to check home BP readings twice daily for a minimum of three days and to provide the measurements for averaging and review. Although the optimal frequency of monitoring is not known, we suggest home BP monitoring at monthly intervals. The preferred technique of self-measured blood pressure measurement is detailed elsewhere. (See  <a class="medical medical_review" href="/d/html/3820.html" rel="external">"Out-of-office blood pressure measurement: Ambulatory and self-measured blood pressure monitoring", section on 'Self-measured blood pressure (SMBP)'</a>.)</p><p>If home BP monitoring is not possible or is unavailable, we use office BP measurements obtained at the patient's monthly nephrology office visit. If available, we prefer automated office blood pressure measurement (AOBP), which provides multiple consecutive unattended BP readings, rather than routine office-based BP measurement. The optimal technique of office-based BP measurement is detailed elsewhere. (See  <a class="medical medical_review" href="/d/html/3879.html" rel="external">"Blood pressure measurement in the diagnosis and management of hypertension in adults", section on 'Office-based blood pressure measurement'</a>.)</p><p>In the general population and among patients with chronic kidney disease, self-recorded BP measurements correlate more closely with the results of 24-hour or daytime ABPM than with office-based measurements [<a href="#rid61">61-64</a>].</p><p class="headingAnchor" id="H10"><span class="h1">BENEFITS OF TREATING HYPERTENSION</span><span class="headingEndMark"> — </span>Multiple studies and meta-analyses of randomized, controlled trials in patients on dialysis have suggested a benefit of using antihypertensive agents to lower blood pressure (BP) on cardiovascular (CV) events and CV mortality [<a href="#rid13">13,65-69</a>]. The best data are from two meta-analyses:</p><p class="bulletIndent1"><span class="glyph">●</span>A 2009 systematic review and meta-analysis of eight randomized, controlled trials that enrolled 1679 patients on dialysis found that lowering BP with antihypertensive therapy was associated with decreased risks of CV events (relative risk [RR] 0.71, 95% CI 0.55-0.92), all-cause mortality (RR 0.80, 95% CI 0.66-0.96), and CV mortality (RR 0.71, 95% CI 0.50-0.99) [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second 2009 meta-analysis including five randomized trials with 1202 patients on hemodialysis showed that, compared with placebo or control therapy, BP lowering with antihypertensive therapy resulted in a 31 percent reduction in the risk of CV events (pooled hazard ratio [HR] 0.69, 95% CI 0.56-0.84) [<a href="#rid69">69</a>].</p><p></p><p class="headingAnchor" id="H11"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The optimal blood pressure (BP) goal and the interventions that are available to treat hypertension in patients on dialysis are discussed here.</p><p class="headingAnchor" id="H3601356681"><span class="h2">Blood pressure target</span><span class="headingEndMark"> — </span>The threshold BP that should be treated is unknown; BP target ranges for patients on dialysis have been extrapolated from studies in the nondialysis patient population. In addition, BP targets may need to be individualized based on patient frailty, expected survival, and symptoms such as dizziness or light-headedness. BP targets for patients on hemodialysis and for patients on peritoneal dialysis are discussed below:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients on hemodialysis</strong> – In patients on hemodialysis, we target an interdialytic BP of &lt;140/80 using home BPs. We preferably use self-measured home BP to achieve this target for reasons discussed above. (See <a class="local">'Monitoring and diagnosis'</a> above.)</p><p></p><p class="bulletIndent1">If interdialytic self-measured home BP is not available, targeting a midweek median intradialytic BP of &lt;140/80 mmHg appears to be a reasonable alternative strategy. We calculate the midweek median BP from all the BPs measured during a midweek dialysis session (eg, on Wednesday for a patient receiving dialysis on Mondays, Wednesdays, and Fridays).</p><p></p><p class="bulletIndent1">We do <strong>not</strong> use a predialysis BP target to control hypertension. Targeting predialysis BPs is not helpful. As an example, one pilot trial evaluated the target predialysis BP in patients receiving dialysis [<a href="#rid70">70</a>]. The trial randomly assigned 126 long-term hemodialysis patients to one of two BP goals: an intensive arm (predialysis systolic BP of 110 to 140 mmHg) and a standard arm (predialysis systolic BP of 155 to 165 mmHg). Compared with patients in the standard arm, those in the intensive arm had a higher risk of recurrent hospitalization, vascular access thrombosis, and intradialytic hypotension.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients on peritoneal dialysis</strong> – In patients on peritoneal dialysis, we target a BP of &lt;130/80 mmHg using home BPs or automated office blood pressure measurement (AOBP), or a target of &lt;140/90 mmHg using routine office-based measurements. We preferably use home BP for reasons discussed above (see <a class="local">'Monitoring and diagnosis'</a> above). The target of &lt;140/90 mmHg is consistent with guidelines from the International Society of Peritoneal Dialysis [<a href="#rid71">71</a>].</p><p></p><p>There are no large-scale trials that define optimal BP targets among patients on hemodialysis or peritoneal dialysis. Our assessment of the best target BP is based upon findings reported in observational studies combined with our clinical experience managing patients on dialysis.</p><p class="headingAnchor" id="H1980489376"><span class="h2">Interventions</span><span class="headingEndMark"> — </span>The two main treatment interventions to control BP are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Reducing the target dry weight to achieve euvolemia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antihypertensive medications</p><p></p><p>If possible, the target dry weight should be adjusted before antihypertensive agents are added. However, patients are often on multiple antihypertensive agents when they start maintenance dialysis. Among such patients, the approach will vary depending on severity of hypertension and hemodynamic stability during dialysis. As an example, in some patients on dialysis, ultrafiltration is limited because of hypotension; such patients may benefit from tapering antihypertensive agents. In other patients who have severe hypertension, antihypertensive agents may need to be continued while the target dry weight is gradually reduced.</p><p class="headingAnchor" id="H12"><span class="h2">Achieving optimal dry weight</span><span class="headingEndMark"> — </span>Reducing the target dry weight gradually can normalize the BP or make the hypertension easier to control in a vast majority of patients on dialysis [<a href="#rid33">33,72</a>]. The exact definition of target dry weight remains uncertain, but multiple definitions have been suggested [<a href="#rid73">73-75</a>]. We believe that the best definition of dry weight is the lowest tolerated weight at which there are minimal signs or symptoms of either hypovolemia or hypervolemia [<a href="#rid76">76</a>].</p><p class="headingAnchor" id="H292493024"><span class="h3">Assessment of volume status</span><span class="headingEndMark"> — </span>A careful clinical assessment of volume status is necessary to achieve an optimal dry weight.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>History and physical examination</strong> – Patient history and physical examination are essential components of the volume status assessment. The patient should be questioned about missing dialysis treatments or cutting them short, since underdialysis commonly leads to volume overload. A recent hospitalization may suggest loss of lean body mass, especially after a catabolic illness such as pneumonia or long bone fracture. Symptoms that suggest orthostatic hypotension (such as lightheadedness) and, for patients on hemodialysis, intradialytic symptoms such as muscle cramps may indicate that the dry weight is below desired. However, muscle cramps may not be a reliable indicator of hypovolemia, especially when they do not improve despite an increase in dry weight.</p><p></p><p class="bulletIndent1">A physical examination includes an assessment for presence of increased jugular venous pulse, peripheral or pulmonary edema, and ascites (suggesting volume overload) at a given weight and BP.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other methods </strong>– If used, other methods of assessing volume status should function as adjuncts, rather than as alternatives, to the clinical assessment of the patient.</p><p></p><p class="bulletIndent1">Bioimpedance analysis [<a href="#rid77">77,78</a>], relative plasma volume (RPV) monitoring [<a href="#rid79">79,80</a>], measurement of the inferior cava diameter [<a href="#rid81">81-83</a>], and plasma natriuretic peptides (particularly atrial and B-type) concentrations [<a href="#rid84">84,85</a>] have been used to assess dry weight. These methods are not commonly used clinically, although studies have suggested utility, particularly of bioimpedance analysis and RPV monitoring [<a href="#rid77">77,79,80</a>]. None of these methods for determining dry weight have demonstrated superiority over clinical assessment alone [<a href="#rid80">80,84,86-88</a>].</p><p></p><p class="bulletIndent1">An emerging strategy to assess volume excess is lung ultrasound, which can be used to measure lung water as a marker of lung congestion. One trial compared lung ultrasound-guided dry weight reduction versus usual care on BP improvement among 71 hemodialysis patients [<a href="#rid89">89-91</a>]. At 12 months, lung ultrasound-guided dry weight reduction was greater in the ultrasound group (-2 versus +0.5 kg), and accompanied by a greater decline in 44-hour ambulatory systolic (6 versus 0.5 mmHg) and diastolic (4 versus 1 mmHg) BP, ultrasound B lines (metric of lung water, -5 lines versus +6 lines), and rate of intradialytic hypotension. However, this was a small trial, and these findings need to be replicated in larger, more diverse populations before it can be introduced into routine clinical care.</p><p></p><p class="headingAnchor" id="H2797629044"><span class="h3">Subclinical volume excess</span><span class="headingEndMark"> — </span>In many patients with hypertension, volume excess may be present despite the clinical appearance of euvolemia (see <a class="local">'Assessment of volume status'</a> above). Therefore, we attempt to reduce dry weight without clinical evidence of volume expansion in the following scenarios:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients just initiating maintenance dialysis who are either hypertensive (as defined above) or who are taking antihypertensive agents</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients on dialysis with worsening BP control of unknown cause</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients on dialysis requiring additional antihypertensive medications, or dose escalations of existing medications, to maintain adequate BP control</p><p></p><p class="headingAnchor" id="H4230467084"><span class="h3">How to reduce target dry weight</span><span class="headingEndMark"> — </span>The reduction in dry weight is best done gradually; we reduce the target dry weight over days to weeks [<a href="#rid7">7,27,30,31,66,92-96</a>]. An important component of successfully attaining a lower dry weight is to minimize fluid accumulation, which, for patients on hemodialysis, predominantly occurs in the interdialytic period.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limit salt intake for all patients</strong> – Limiting dietary salt is the best way to limit fluid intake because salt intake drives thirst. It is not helpful to restrict fluid without restricting salt.</p><p></p><p class="bulletIndent1">All patients should adhere to a restricted salt diet (1500 to 2000 mg of sodium/day) [<a href="#rid66">66,97,98</a>]. However, patient adherence to a low-sodium diet is often suboptimal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients on hemodialysis</strong> – We reduce the target dry weight by approximately 0.5 kg per dialysis session. In patients who are unable to tolerate this, we attempt 0.2 kg per session.</p><p></p><p class="bulletIndent1">Patients should minimize interdialytic weight gain in order to limit the amount of fluid that needs to be removed in an individual session. Patients with greater weight gain in between dialysis sessions (eg, &gt;2 to 3 kg) often have difficulty achieving the previous target dry weight, especially at optimal rates of ultrafiltration. (See  <a class="medical medical_review" href="/d/html/1836.html" rel="external">"Prescribing and assessing adequate hemodialysis", section on 'Patient-specific parameters'</a>.)</p><p></p><p class="bulletIndent1">In patients who have clinical evidence of volume excess but in whom it is difficult to reduce the target dry weight, we use the following approach:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Increase dialysis time </strong>– Increasing the length or frequency of sessions is often effective in reducing target dry weight [<a href="#rid99">99</a>].</p><p></p><p class="bulletIndent2">The utility of lengthier dialysis sessions was demonstrated in a large dialysis center in Tassin, France, where a standard regimen is eight hours, three times per week [<a href="#rid31">31,100-102</a>]. This regimen was associated with the maintenance of normotension without medications in almost all patients [<a href="#rid31">31,100-102</a>]. The improved BP was largely attributed to optimal volume control, although other factors may contribute, such as decreased afferent renal nerve activity and efferent sympathetic activation [<a href="#rid36">36</a>]. However, this regimen is not widely used in in-center hemodialysis. (See  <a class="medical medical_review" href="/d/html/1847.html" rel="external">"Patient survival and maintenance dialysis", section on 'Adequacy of dialysis'</a>.)</p><p></p><p class="bulletIndent2">The efficacy of more frequent dialysis in achieving BP control is demonstrated by nocturnal hemodialysis, in which dialysis is performed six or seven nights a week during sleep (usually 6 to 12 hours in total) [<a href="#rid103">103</a>]. Almost all patients become normotensive without medications. (See  <a class="medical medical_review" href="/d/html/1904.html" rel="external">"Technical aspects of nocturnal hemodialysis"</a>.)</p><p></p><p class="bulletIndent2">Short daily hemodialysis may also be associated with better BP control. (See  <a class="medical medical_review" href="/d/html/1898.html" rel="external">"Short daily hemodialysis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Reduce dialysate sodium </strong>– If increasing the dialysis time is ineffective, we reduce the dialysate sodium concentration.</p><p></p><p class="bulletIndent2">The use of standard sodium prescriptions leads to decreased sodium loss during dialysis and mild increases in serum sodium values postdialysis [<a href="#rid104">104</a>]. This results in increased thirst, large interdialytic weight gains, and corresponding difficulty achieving an optimal dry weight. A lower dialysate sodium concentration may result in lower antihypertensive medication requirements and decreased BP [<a href="#rid105">105</a>]. The dialysate sodium should be reduced gradually (ie, 1 mEq/L every three to four weeks) to approximately 135 mEq/L. Because lower dialysate sodium concentrations may be associated with a greater risk of intradialytic hypotension [<a href="#rid106">106</a>], patients should be encouraged to report symptoms of lightheadedness, muscle cramps, and nausea that occur during dialysis.</p><p></p><p class="bulletIndent2">The dialysate sodium may be reduced in a fixed or variable fashion.</p><p></p><p class="bulletIndent2">The effect of a variable reduction in dialysate sodium (also known as sodium modeling) on BP was evaluated in one randomized, crossover study [<a href="#rid107">107</a>]. A programmed decrease in sodium dialysate concentration from 155 to 135 mEq/L was compared with the standard stable sodium dialysate concentration of 140 mEq/L [<a href="#rid107">107</a>]. Postdialysis BP and antihypertensive use were reduced when patients were dialyzed with a variable sodium prescription.</p><p></p><p class="bulletIndent2">A fixed lower dialysate sodium concentration in combination with sodium restriction was evaluated in a small, uncontrolled study [<a href="#rid108">108</a>]. Eight hypertensive hemodialysis patients were dialyzed against a gradually lowered sodium dialysate concentration (140 to 135 mEq/L at a rate of 1 mEq/L every three to four weeks) and were encouraged to limit salt intake to &lt;6 g/day [<a href="#rid108">108</a>]. At study end, the mean arterial pressure was lower, and antihypertensive medications were no longer required in four patients. However, adherence to the diet was difficult, and the frequency of muscle cramps during dialysis was increased. This regimen engenders the risk of episodic hypotension and should be instituted cautiously (ie, with close observation).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients on peritoneal dialysis</strong> – For patients on peritoneal dialysis who do not have clinical evidence of volume expansion but in whom we attempt to reduce target dry weight (see <a class="local">'Subclinical volume excess'</a> above), we challenge the dry weight by 0.5 to 1.0 kg per week. In patients who have clinical evidence of volume expansion, we reduce the target dry weight more rapidly. The approach to volume control for patients on peritoneal dialysis is detailed separately. (See  <a class="medical medical_review" href="/d/html/1914.html" rel="external">"Management of hypervolemia in patients on peritoneal dialysis"</a>.)</p><p></p><p class="headingAnchor" id="H14"><span class="h2">Antihypertensive medications</span><span class="headingEndMark"> — </span>Many patients on dialysis will require antihypertensive agents to control BP despite achieving optimal dry weight. The optimal antihypertensive regimen for patients on dialysis is not known. Our approach to managing hypertension among patients on dialysis who require medications after optimization of volume status (see <a class="local">'Achieving optimal dry weight'</a> above) is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Our first-choice antihypertensive agent is a beta blocker (BB), even among patients previously controlled with another agent. Among the available BBs, we prefer <a class="drug drug_general" data-topicid="8940" href="/d/drug information/8940.html" rel="external">atenolol</a>, but other BBs are acceptable alternatives. Dosing varies by modality of dialysis:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among patients receiving hemodialysis, we dose <a class="drug drug_general" data-topicid="8940" href="/d/drug information/8940.html" rel="external">atenolol</a> postdialysis thrice weekly. We typically start it at 25 or 50 mg depending upon the severity of hypertension. The maximum dose that we use among patients on hemodialysis is 100 mg thrice weekly.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among patients receiving peritoneal dialysis, we dose <a class="drug drug_general" data-topicid="8940" href="/d/drug information/8940.html" rel="external">atenolol</a> once daily. We typically start it at 25 or 50 mg once daily depending upon the severity of hypertension. The maximum daily dose that we use among patients on peritoneal dialysis is 50 mg once daily.</p><p></p><p class="bulletIndent1">A dose-limiting side effect of BBs is bradycardia. Among patients with symptomatic bradycardia from BBs (eg, lightheadedness, presyncope or syncope, exercise intolerance), we reduce the dose of the BB. Among patients with asymptomatic bradycardia, we avoid increasing the BB dose once the heart rate is 50 beats per minute or below and reduce the dose when the heart rate is 40 beats per minute or below. Side effects of BBs are discussed at length elsewhere. (See  <a class="medical medical_review" href="/d/html/967.html" rel="external">"Major side effects of beta blockers"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Our second-choice agent is a dihydropyridine calcium channel blocker (CCB), such as <a class="drug drug_general" data-topicid="8627" href="/d/drug information/8627.html" rel="external">amlodipine</a> 10 mg dosed daily. We add amlodipine among patients who have BPs that are not adequately controlled with the maximum dose BB or among patients who develop intolerable side effects (eg, bradycardia) to the BB. CCBs are not cleared by dialysis and, therefore, do not need to be supplemented or dosed postdialysis. Side effects of CCBs are discussed at length elsewhere. (See  <a class="medical medical_review" href="/d/html/3832.html" rel="external">"Major side effects and safety of calcium channel blockers"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Our third-choice agent is an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB). We add an ACE inhibitor or ARB among patients with BPs that are inadequately controlled with a BB and a CCB and among patients who have inadequately controlled BP with one and intolerance to another. However, for patients on dialysis who still make urine, some experts prefer to use an ACE inhibitor or ARB as first-line antihypertensive therapy because of the potential benefit of preserving residual kidney function. (See  <a class="medical medical_review" href="/d/html/1941.html" rel="external">"Residual kidney function in kidney failure", section on 'Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers'</a>.)</p><p></p><p class="bulletIndent1">Side effects of ACE inhibitors and ARBs are discussed below and at length elsewhere. (See  <a class="medical medical_review" href="/d/html/3816.html" rel="external">"Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers"</a>.) </p><p></p><p>The management of patients who remain hypertensive despite maximally tolerated doses of BB, CCB, and either ACE inhibitor or ARB is discussed below. (See <a class="local">'Resistant hypertension'</a> below.)</p><p>Our preference for BBs as the first-line agent is based upon findings from the Hypertension in Hemodialysis Patients Treated with <a class="drug drug_general" data-topicid="8940" href="/d/drug information/8940.html" rel="external">Atenolol</a> or <a class="drug drug_general" data-topicid="9565" href="/d/drug information/9565.html" rel="external">Lisinopril</a> trial in which 200 patients were randomly assigned to receive either drug [<a href="#rid55">55</a>]. At 12 months, compared with lisinopril, atenolol led to a numerically greater reduction in BP using the 44-hour interdialytic ambulatory BP monitoring (mean reduction -21/-13 versus -18/-10 mmHg) and the self-measured home BPs (mean reduction -25/-12 versus -19/-10 mmHg); these differences were not statistically significant. Over the course of the trial, compared with patients in the lisinopril group, those in the atenolol group required fewer antihypertensive medications despite a lesser degree of reduction in their dry weight. Additionally, there were fewer serious cardiovascular (CV) events including CV death, myocardial infarction, stroke, and hospitalization for heart failure in the atenolol group compared with the lisinopril group (20 events among 16 patients versus 43 events among 28 patients), leading to early termination of the trial.</p><p>Our next preference for CCBs is based upon their efficacy and tolerance in addition to their beneficial effect on CV outcomes in dialysis patients [<a href="#rid109">109-111</a>]. In one trial, compared with patients randomly assigned to placebo, those assigned to <a class="drug drug_general" data-topicid="8627" href="/d/drug information/8627.html" rel="external">amlodipine</a> had a reduction in the composite of all-cause mortality and CV events (hazard ratio [HR] 0.53, 95% CI 0.31-0.93). Amlodipine led to a clinically meaningful but statistically nonsignificant reduction in all-cause mortality (12 percent with amlodipine and 17 percent with placebo) [<a href="#rid111">111</a>].</p><p>We do not use nondihydropyridine CCBs (such as <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> or <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a>) because drug interactions with these agents are common and bradycardia can occur if dosed concomitantly with a BB.</p><p>We offer ACE inhibitors and ARBs only to patients who have an elevated BP despite maximally tolerated doses of BBs and CCBs. This is because ACE inhibitors or ARBs lead to modest reduction in BPs and no reduction in fatal and nonfatal CV events. As examples, in a 2010 meta-analysis of trial data including 837 patients on hemodialysis, there was no significant reduction in BP or fatal and nonfatal CV events among patients treated with ACE inhibitors or ARBs compared with those in the standard care group [<a href="#rid112">112</a>]. In a subsequent trial of 469 hemodialysis patients, compared with standard care, patients randomly assigned to <a class="drug drug_general" data-topicid="10061" href="/d/drug information/10061.html" rel="external">olmesartan</a> had no significant reduction in BP (mean difference in BP of 0.9 mmHg) or in the incidence of fatal and nonfatal CV events (HR 1.00, 95% CI 0.62-1.52) [<a href="#rid113">113</a>]. Another smaller trial reported similar findings [<a href="#rid114">114</a>].</p><p>In addition, ACE inhibitors and ARBs can cause hyperkalemia [<a href="#rid55">55</a>], hypotension [<a href="#rid55">55,114</a>], reduction in the effect of erythropoiesis-stimulating agents, and anaphylactoid reaction in patients dialyzed with an AN69 dialyzer [<a href="#rid115">115</a>], thereby lowering the overall appeal of these agents. (See  <a class="medical medical_review" href="/d/html/3816.html" rel="external">"Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers"</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">RESISTANT HYPERTENSION</span><span class="headingEndMark"> — </span>Some dialysis patients are resistant to both volume control and initial antihypertensive medications. Factors that can contribute to resistant hypertension include (see  <a class="medical medical_review" href="/d/html/3818.html" rel="external">"Definition, risk factors, and evaluation of resistant hypertension"</a> and  <a class="medical medical_review" href="/d/html/3819.html" rel="external">"Treatment of resistant hypertension"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Nonadherence to the antihypertensive regimen (see  <a class="medical medical_review" href="/d/html/3845.html" rel="external">"Patient adherence and the treatment of hypertension"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concurrent use of a medication that can raise blood pressure (BP; such as nonsteroidal anti-inflammatory drugs [NSAIDs] or erythropoietin-stimulating agents) (see <a class="local">'Pathogenesis'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inadequate dialysis (less than four hours per session, thrice weekly) (see  <a class="medical medical_review" href="/d/html/1836.html" rel="external">"Prescribing and assessing adequate hemodialysis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renovascular hypertension (see  <a class="medical medical_review" href="/d/html/3825.html" rel="external">"Establishing the diagnosis of renovascular hypertension"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Expanding cyst size among patients with polycystic kidney disease (see  <a class="medical medical_review" href="/d/html/1675.html" rel="external">"Autosomal dominant polycystic kidney disease (ADPKD): Evaluation and management of hypertension"</a>)</p><p></p><p>Nonadherence with medications is a common cause of resistant hypertension. Chronically nonadherent hypertensive patients who refuse to take medications at home may benefit from the administration of long-acting antihypertensive medications in the dialysis unit [<a href="#rid116">116</a>]. </p><p>If a treatable cause cannot be found, the vasodilator <a class="drug drug_general" data-topicid="9655" href="/d/drug information/9655.html" rel="external">minoxidil</a> may be added to the antihypertensive regimen. A central sympathetic agonist (ie, <a class="drug drug_general" data-topicid="9285" href="/d/drug information/9285.html" rel="external">clonidine</a> or <a class="drug drug_general" data-topicid="8510" href="/d/drug information/8510.html" rel="external">guanfacine</a>) is used less frequently than minoxidil because of adverse effects involving the central nervous system, and because of the possible potentiation of beta blocker (BB) mediated bradycardia. Some clinicians have found clonidine patches to be effective and well tolerated, but this is not a universal finding [<a href="#rid115">115,116</a>]. Guanfacine may be less sedating than clonidine.</p><p>We generally do <strong>not</strong> use mineralocorticoid receptor antagonists in patients on dialysis because of the potential risk of hyperkalemia [<a href="#rid117">117-119</a>]. Mineralocorticoid receptor antagonists (eg, <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a>) are commonly used in nondialysis patients with resistant hypertension, and two trials reported very large benefits on cardiovascular (CV) mortality from spironolactone in patients receiving dialysis [<a href="#rid120">120,121</a>]. Effects of this magnitude are rarely if ever observed in rigorous CV trials; in addition, the findings have not been independently confirmed.</p><p>More data are needed before renal denervation can be recommended in patients on dialysis (see  <a class="medical medical_review" href="/d/html/3819.html" rel="external">"Treatment of resistant hypertension", section on 'Renal denervation'</a>). Renal denervation is a therapy in which sympathetic nerves innervating the kidney are ablated for BP control. This method was evaluated in a small nonrandomized trial of 24 patients on hemodialysis who had resistant hypertension despite maximal medical therapy with confirmed adherence [<a href="#rid122">122</a>]. Over a follow-up period of one year, patients treated with renal denervation in addition to medical therapy had a substantial and sustained reduction in BP compared with patients on medical therapy alone (32/18 mmHg versus 7/3 mmHg).</p><p>Bilateral nephrectomy is no longer performed ever since effective antihypertensive medications became available.</p><p class="headingAnchor" id="H22"><span class="h1">HYPERTENSION DURING HEMODIALYSIS</span><span class="headingEndMark"> — </span>Some patients develop paradoxical hypertension in the later stages of the hemodialysis treatment, a time at which most of the excess fluid has already been removed. Limited observational evidence suggests that this increase in blood pressure (BP) is associated with adverse outcomes [<a href="#rid123">123</a>]. The pathogenesis is unclear, although evidence suggests that contributing factors include volume excess [<a href="#rid124">124</a>], interdialytic hypertension [<a href="#rid125">125</a>], and altered nitric oxide/endothelin-1 balance and/or endothelial dysfunction [<a href="#rid126">126,127</a>].</p><p>The optimal approach to intradialytic hypertension is not known. The following interventions, which may be used in combination but should be initiated or adjusted singly, may be effective:</p><p class="bulletIndent1"><span class="glyph">●</span>Challenging the dry weight [<a href="#rid79">79</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Switching <a class="drug drug_general" data-topicid="8940" href="/d/drug information/8940.html" rel="external">atenolol</a> to <a class="drug drug_general" data-topicid="9208" href="/d/drug information/9208.html" rel="external">carvedilol</a>, which blocks endothelin-1 release. In a 12-week pilot study, the initiation of carvedilol titrated to 50 mg twice daily was associated with a decrease in the frequency of intradialytic hypertensive episodes from 77 to 28 percent of hemodialysis sessions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Using a dialysate sodium concentration that is lower than the patient's serum sodium. The efficacy of this intervention was suggested by a three-week randomized, crossover trial that compared the effect of high- and low-dialysate sodium concentrations on systolic BP among 16 patients with intradialytic hypertension [<a href="#rid128">128</a>].</p><p></p><p class="headingAnchor" id="H4109443662"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112932.html" rel="external">"Society guideline links: Dialysis"</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and pathogenesis</strong> – Hypertension is a common finding in patients on dialysis, particularly at initiation. Volume expansion is the major cause of hypertension in patients on dialysis, although sympathetic overactivity, activation of the renin-angiotensin system, and arteriosclerosis also contribute. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood pressure (BP)</strong> <strong>assessment</strong> – For patients on dialysis, we use self-recorded home BPs to monitor BP and diagnose hypertension. Self-recorded home BP readings are efficient, accurate, and correlate with readings obtained by ambulatory blood pressure monitoring (ABPM). For patients on hemodialysis, we do not use pre- and postdialysis BP measurements to diagnose hypertension and inform antihypertensive therapy, since these measurements do not correlate with ABPM or with clinical outcomes. (See <a class="local">'Monitoring and diagnosis'</a> above.)</p><p></p><p class="bulletIndent1">If home BP monitoring is not possible or feasible, our approach varies by dialysis modality:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients on hemodialysis, we use the midweek median intradialytic systolic BP. (See <a class="local">'Hemodialysis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients on peritoneal dialysis, we use office BP measurements obtained at the patient's monthly nephrology office visit. If available, we prefer automated office blood pressure measurement (AOBP), which provides multiple consecutive unattended BP readings, rather than routine office-based BP measurement. (See <a class="local">'Peritoneal dialysis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>BP target</strong> – The threshold BP that should be treated is unknown.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients on hemodialysis, we suggest targeting an interdialytic BP of &lt;140/80 mmHg using home BPs (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). If interdialytic home BPs are not available, targeting a midweek median intradialytic BP of &lt;140/80 mmHg is a reasonable alternative strategy. (See <a class="local">'Blood pressure target'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients on peritoneal dialysis, we suggest targeting a BP of &lt;130/80 mmHg using home BPs (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). If home BPs are unavailable, we target a BP of &lt;130/80 mmHg using AOBP, or a target of &lt;140/90 mmHg using routine office-based measurements. (See <a class="local">'Blood pressure target'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment interventions</strong> – The primary strategy to improve BP in a patient on dialysis is to optimize volume status. BP treatment consists of reducing target dry weight to achieve euvolemia and pharmacologic interventions. We use the history and physical examination to assess volume status and individualize optimal target dry weight. (See <a class="local">'Interventions'</a> above and <a class="local">'Assessment of volume status'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reducing target dry weight</strong> – We reduce the target weight over days to weeks. An important component of successfully attaining a lower dry weight is to minimize fluid accumulation, which, for patients on hemodialysis, predominantly occurs in the interdialytic period. Limiting salt intake prevents thirst and is the best way to limit fluid intake. For some patients on hemodialysis, increasing the length and/or frequency of dialysis sessions is necessary to achieve an optimal dry weight. (See <a class="local">'How to reduce target dry weight'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antihypertensive medications</strong> – Many patients on dialysis require antihypertensive agents. The optimal agent is not known. Our approach is as follows (see <a class="local">'Antihypertensive medications'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among patients on dialysis who need antihypertensive therapy, we suggest treatment with a beta blocker (BB) rather than another antihypertensive agent (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="8940" href="/d/drug information/8940.html" rel="external">Atenolol</a> is our usual choice, but other BBs are acceptable alternatives. Among patients on hemodialysis, we dose atenolol thrice weekly with a starting dose of 25 mg up to a maximum of 100 mg. Among patients on peritoneal dialysis, we dose atenolol daily with a starting dose of 25 mg up to a maximum dose of 50 mg. We reduce the dose of the BB for symptomatic bradycardia and if the heart rate is at or below 40 beats per minute. We stop increasing the dose of the BB if the heart rate is at or below 50 beats per minute.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among patients who have BPs that are not adequately controlled with the maximum dose BB or who develop intolerable side effects (eg, bradycardia) to the BB, we add calcium channel blockers (CCBs), such as <a class="drug drug_general" data-topicid="8627" href="/d/drug information/8627.html" rel="external">amlodipine</a> 10 mg.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among patients who have BPs that are inadequately controlled with a BB and a CCB and among patients who have inadequately controlled BP with one and intolerance to another, we add an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB). However, for patients on dialysis who still make urine, some experts prefer to use an ACE inhibitor or ARB as first-line antihypertensive therapy because of the potential benefit of preserving residual kidney function. (See  <a class="medical medical_review" href="/d/html/1941.html" rel="external">"Residual kidney function in kidney failure", section on 'Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resistant hypertension</strong> – Patients who have BPs that are uncontrolled despite use of maximally tolerated doses of a BB, CCB, and an ACE or ARB have resistant hypertension. Such patients require an evaluation for possible underlying causes and possible treatment with additional antihypertensive agents such as <a class="drug drug_general" data-topicid="9655" href="/d/drug information/9655.html" rel="external">minoxidil</a>. (See <a class="local">'Resistant hypertension'</a> above.)</p><p></p><p class="headingAnchor" id="H2874866830"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges William Henrich, MD, MACP and Lionel U Mailloux, MD, FACP, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mailloux LU, Haley WE. Hypertension in the ESRD patient: pathophysiology, therapy, outcomes, and future directions. Am J Kidney Dis 1998; 32:705.</a></li><li class="breakAll">1995 Annual Report. ESRD core indicators project. Opportunities to improve care for adult in-center hemodialysis patients. Health Care Financing Administration; DHHS, Baltimore, MD 1996.</li><li><a class="nounderline abstract_t">Rocco MV, Flanigan MJ, Beaver S, et al. Report from the 1995 Core Indicators for Peritoneal Dialysis Study Group. Am J Kidney Dis 1997; 30:165.</a></li><li><a class="nounderline abstract_t">Rahman M, Dixit A, Donley V, et al. Factors associated with inadequate blood pressure control in hypertensive hemodialysis patients. Am J Kidney Dis 1999; 33:498.</a></li><li><a class="nounderline abstract_t">Agarwal R, Nissenson AR, Batlle D, et al. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med 2003; 115:291.</a></li><li><a class="nounderline abstract_t">Agarwal R, Flynn J, Pogue V, et al. Assessment and management of hypertension in patients on dialysis. J Am Soc Nephrol 2014; 25:1630.</a></li><li><a class="nounderline abstract_t">Zucchelli P, Santoro A, Zuccala A. Genesis and control of hypertension in hemodialysis patients. Semin Nephrol 1988; 8:163.</a></li><li><a class="nounderline abstract_t">Rahman M, Fu P, Sehgal AR, Smith MC. Interdialytic weight gain, compliance with dialysis regimen, and age are independent predictors of blood pressure in hemodialysis patients. Am J Kidney Dis 2000; 35:257.</a></li><li><a class="nounderline abstract_t">Alborzi P, Patel N, Agarwal R. Home blood pressures are of greater prognostic value than hemodialysis unit recordings. Clin J Am Soc Nephrol 2007; 2:1228.</a></li><li><a class="nounderline abstract_t">Agarwal R. Blood pressure and mortality among hemodialysis patients. Hypertension 2010; 55:762.</a></li><li><a class="nounderline abstract_t">Port FK, Hulbert-Shearon TE, Wolfe RA, et al. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis 1999; 33:507.</a></li><li><a class="nounderline abstract_t">Zager PG, Nikolic J, Brown RH, et al. "U" curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int 1998; 54:561.</a></li><li><a class="nounderline abstract_t">Udayaraj UP, Steenkamp R, Caskey FJ, et al. Blood pressure and mortality risk on peritoneal dialysis. Am J Kidney Dis 2009; 53:70.</a></li><li><a class="nounderline abstract_t">Schömig M, Eisenhardt A, Ritz E. Controversy on optimal blood pressure on haemodialysis: normotensive blood pressure values are essential for survival. Nephrol Dial Transplant 2001; 16:469.</a></li><li><a class="nounderline abstract_t">Li Z, Lacson E Jr, Lowrie EG, et al. The epidemiology of systolic blood pressure and death risk in hemodialysis patients. Am J Kidney Dis 2006; 48:606.</a></li><li><a class="nounderline abstract_t">Tentori F, Hunt WC, Rohrscheib M, et al. Which targets in clinical practice guidelines are associated with improved survival in a large dialysis organization? J Am Soc Nephrol 2007; 18:2377.</a></li><li><a class="nounderline abstract_t">Robinson BM, Tong L, Zhang J, et al. Blood pressure levels and mortality risk among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2012; 82:570.</a></li><li><a class="nounderline abstract_t">Salem MM. Hypertension in the haemodialysis population: any relationship to 2-years survival? Nephrol Dial Transplant 1999; 14:125.</a></li><li><a class="nounderline abstract_t">Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, et al. Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: the 58th annual fall conference and scientific sessions. Hypertension 2005; 45:811.</a></li><li><a class="nounderline abstract_t">Stidley CA, Hunt WC, Tentori F, et al. Changing relationship of blood pressure with mortality over time among hemodialysis patients. J Am Soc Nephrol 2006; 17:513.</a></li><li><a class="nounderline abstract_t">Goldfarb-Rumyantzev AS, Baird BC, Leypoldt JK, Cheung AK. The association between BP and mortality in patients on chronic peritoneal dialysis. Nephrol Dial Transplant 2005; 20:1693.</a></li><li><a class="nounderline abstract_t">Afshinnia F, Zaky ZS, Metireddy M, Segal JH. Reverse Epidemiology of Blood Pressure in Peritoneal Dialysis Associated with Dynamic Deterioration of Left Ventricular Function. Perit Dial Int 2016; 36:154.</a></li><li><a class="nounderline abstract_t">Bansal N, McCulloch CE, Rahman M, et al. Blood pressure and risk of all-cause mortality in advanced chronic kidney disease and hemodialysis: the chronic renal insufficiency cohort study. Hypertension 2015; 65:93.</a></li><li><a class="nounderline abstract_t">Argilés A, Lorho R, Servel MF, et al. Seasonal modifications in blood pressure are mainly related to interdialytic body weight gain in dialysis patients. Kidney Int 2004; 65:1795.</a></li><li><a class="nounderline abstract_t">Nongnuch A, Campbell N, Stern E, et al. Increased postdialysis systolic blood pressure is associated with extracellular overhydration in hemodialysis outpatients. Kidney Int 2015; 87:452.</a></li><li><a class="nounderline abstract_t">Salem MM. Hypertension in the hemodialysis population: a survey of 649 patients. Am J Kidney Dis 1995; 26:461.</a></li><li><a class="nounderline abstract_t">Agarwal R, Alborzi P, Satyan S, Light RP. Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. Hypertension 2009; 53:500.</a></li><li><a class="nounderline abstract_t">Fishbane S, Natke E, Maesaka JK. Role of volume overload in dialysis-refractory hypertension. Am J Kidney Dis 1996; 28:257.</a></li><li><a class="nounderline abstract_t">Lins RL, Elseviers M, Rogiers P, et al. Importance of volume factors in dialysis related hypertension. Clin Nephrol 1997; 48:29.</a></li><li><a class="nounderline abstract_t">Vertes V, Cangiano JL, Berman LB, Gould A. Hypertension in end-stage renal disease. N Engl J Med 1969; 280:978.</a></li><li><a class="nounderline abstract_t">Charra B, Calemard E, Ruffet M, et al. Survival as an index of adequacy of dialysis. Kidney Int 1992; 41:1286.</a></li><li><a class="nounderline abstract_t">Ozkahya M, Töz H, Unsal A, et al. Treatment of hypertension in dialysis patients by ultrafiltration: role of cardiac dilatation and time factor. Am J Kidney Dis 1999; 34:218.</a></li><li><a class="nounderline abstract_t">Günal AI, Duman S, Ozkahya M, et al. Strict volume control normalizes hypertension in peritoneal dialysis patients. Am J Kidney Dis 2001; 37:588.</a></li><li><a class="nounderline abstract_t">Hoenich NA, Levin NW. Can technology solve the clinical problem of 'dry weight'? Nephrol Dial Transplant 2003; 18:647.</a></li><li><a class="nounderline abstract_t">Aşci G, Ozkahya M, Duman S, et al. Volume control associated with better cardiac function in long-term peritoneal dialysis patients. Perit Dial Int 2006; 26:85.</a></li><li><a class="nounderline abstract_t">Converse RL Jr, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327:1912.</a></li><li><a class="nounderline abstract_t">Agarwal R, Light RP. Arterial stiffness and interdialytic weight gain influence ambulatory blood pressure patterns in hemodialysis patients. Am J Physiol Renal Physiol 2008; 294:F303.</a></li><li><a class="nounderline abstract_t">Georgianos PI, Agarwal R. Aortic Stiffness, Ambulatory Blood Pressure, and Predictors of Response to Antihypertensive Therapy in Hemodialysis. Am J Kidney Dis 2015; 66:305.</a></li><li><a class="nounderline abstract_t">Shichiri M, Hirata Y, Ando K, et al. Plasma endothelin levels in hypertension and chronic renal failure. Hypertension 1990; 15:493.</a></li><li><a class="nounderline abstract_t">Koyama H, Tabata T, Nishzawa Y, et al. Plasma endothelin levels in patients with uraemia. Lancet 1989; 1:991.</a></li><li><a class="nounderline abstract_t">Suzuki N, Matsumoto H, Miyauchi T, et al. Endothelin-3 concentrations in human plasma: the increased concentrations in patients undergoing haemodialysis. Biochem Biophys Res Commun 1990; 169:809.</a></li><li><a class="nounderline abstract_t">Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339:572.</a></li><li><a class="nounderline abstract_t">Raine AE, Bedford L, Simpson AW, et al. Hyperparathyroidism, platelet intracellular free calcium and hypertension in chronic renal failure. Kidney Int 1993; 43:700.</a></li><li><a class="nounderline abstract_t">Goldsmith DJ, Covic AA, Venning MC, Ackrill P. Blood pressure reduction after parathyroidectomy for secondary hyperparathyroidism: further evidence implicating calcium homeostasis in blood pressure regulation. Am J Kidney Dis 1996; 27:819.</a></li><li><a class="nounderline abstract_t">Desir GV. Regulation of blood pressure and cardiovascular function by renalase. Kidney Int 2009; 76:366.</a></li><li><a class="nounderline abstract_t">Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension 2020; 75:1334.</a></li><li><a class="nounderline abstract_t">Gross ML, Ritz E. Hypertrophy and fibrosis in the cardiomyopathy of uremia--beyond coronary heart disease. Semin Dial 2008; 21:308.</a></li><li><a class="nounderline abstract_t">Siu AL, U.S. Preventive Services Task Force. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2015; 163:778.</a></li><li><a class="nounderline abstract_t">Agarwal R, Light RP. Chronobiology of arterial hypertension in hemodialysis patients: implications for home blood pressure monitoring. Am J Kidney Dis 2009; 54:693.</a></li><li><a class="nounderline abstract_t">Sankaranarayanan N, Santos SF, Peixoto AJ. Blood pressure measurement in dialysis patients. Adv Chronic Kidney Dis 2004; 11:134.</a></li><li><a class="nounderline abstract_t">Peixoto AJ, Santos SF, Mendes RB, et al. Reproducibility of ambulatory blood pressure monitoring in hemodialysis patients. Am J Kidney Dis 2000; 36:983.</a></li><li><a class="nounderline abstract_t">Agarwal R, Andersen MJ, Bishu K, Saha C. Home blood pressure monitoring improves the diagnosis of hypertension in hemodialysis patients. Kidney Int 2006; 69:900.</a></li><li><a class="nounderline abstract_t">Agarwal R. How should hypertension be assessed and managed in hemodialysis patients? Home BP, not dialysis unit BP, should be used for managing hypertension. Semin Dial 2007; 20:402.</a></li><li><a class="nounderline abstract_t">Agarwal R. Managing hypertension using home blood pressure monitoring among haemodialysis patients--a call to action. Nephrol Dial Transplant 2010; 25:1766.</a></li><li><a class="nounderline abstract_t">Agarwal R, Sinha AD, Pappas MK, et al. Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. Nephrol Dial Transplant 2014; 29:672.</a></li><li><a class="nounderline abstract_t">Bansal N, Glidden DV, Mehrotra R, et al. Treating Home Versus Predialysis Blood Pressure Among In-Center Hemodialysis Patients: A Pilot Randomized Trial. Am J Kidney Dis 2021; 77:12.</a></li><li><a class="nounderline abstract_t">Agarwal R, Andersen MJ, Light RP. Location not quantity of blood pressure measurements predicts mortality in hemodialysis patients. Am J Nephrol 2008; 28:210.</a></li><li><a class="nounderline abstract_t">Agarwal R, Peixoto AJ, Santos SF, Zoccali C. Pre- and postdialysis blood pressures are imprecise estimates of interdialytic ambulatory blood pressure. Clin J Am Soc Nephrol 2006; 1:389.</a></li><li><a class="nounderline abstract_t">Agarwal R, Metiku T, Tegegne GG, et al. Diagnosing hypertension by intradialytic blood pressure recordings. Clin J Am Soc Nephrol 2008; 3:1364.</a></li><li><a class="nounderline abstract_t">Agarwal R, Light RP. Median intradialytic blood pressure can track changes evoked by probing dry-weight. Clin J Am Soc Nephrol 2010; 5:897.</a></li><li><a class="nounderline abstract_t">Viera AJ, Yano Y, Lin FC, et al. Does This Adult Patient Have Hypertension?: The Rational Clinical Examination Systematic Review. JAMA 2021; 326:339.</a></li><li><a class="nounderline abstract_t">Pickering TG, Miller NH, Ogedegbe G, et al. Call to action on use and reimbursement for home blood pressure monitoring: executive summary: a joint scientific statement from the American Heart Association, American Society Of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension 2008; 52:1.</a></li><li><a class="nounderline abstract_t">Andersen MJ, Khawandi W, Agarwal R. Home blood pressure monitoring in CKD. Am J Kidney Dis 2005; 45:994.</a></li><li><a class="nounderline abstract_t">Verberk WJ, Kroon AA, Kessels AG, de Leeuw PW. Home blood pressure measurement: a systematic review. J Am Coll Cardiol 2005; 46:743.</a></li><li><a class="nounderline abstract_t">Mailloux LU, Levey AS. Hypertension in patients with chronic renal disease. Am J Kidney Dis 1998; 32:S120.</a></li><li><a class="nounderline abstract_t">Locatelli F, Covic A, Chazot C, et al. Hypertension and cardiovascular risk assessment in dialysis patients. Nephrol Dial Transplant 2004; 19:1058.</a></li><li><a class="nounderline abstract_t">Takeda A, Toda T, Fujii T, et al. Discordance of influence of hypertension on mortality and cardiovascular risk in hemodialysis patients. Am J Kidney Dis 2005; 45:112.</a></li><li><a class="nounderline abstract_t">Heerspink HJ, Ninomiya T, Zoungas S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 2009; 373:1009.</a></li><li><a class="nounderline abstract_t">Agarwal R, Sinha AD. Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. Hypertension 2009; 53:860.</a></li><li><a class="nounderline abstract_t">Miskulin DC, Gassman J, Schrader R, et al. BP in Dialysis: Results of a Pilot Study. J Am Soc Nephrol 2018; 29:307.</a></li><li><a class="nounderline abstract_t">Wang AY, Brimble KS, Brunier G, et al. ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part I - Assessment and Management of Various Cardiovascular Risk Factors. Perit Dial Int 2015; 35:379.</a></li><li><a class="nounderline abstract_t">Abu-Alfa AK, Burkart J, Piraino B, et al. Approach to fluid management in peritoneal dialysis: a practical algorithm. Kidney Int Suppl 2002; :S8.</a></li><li><a class="nounderline abstract_t">Agarwal R, Andersen MJ, Pratt JH. On the importance of pedal edema in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3:153.</a></li><li><a class="nounderline abstract_t">Abraham PA, Opsahl JA, Keshaviah PR, et al. Body fluid spaces and blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. Am J Kidney Dis 1990; 16:438.</a></li><li><a class="nounderline abstract_t">Charra B, Laurent G, Chazot C, et al. Clinical assessment of dry weight. Nephrol Dial Transplant 1996; 11 Suppl 2:16.</a></li><li><a class="nounderline abstract_t">Sinha AD, Agarwal R. Can chronic volume overload be recognized and prevented in hemodialysis patients? The pitfalls of the clinical examination in assessing volume status. Semin Dial 2009; 22:480.</a></li><li><a class="nounderline abstract_t">Onofriescu M, Hogas S, Voroneanu L, et al. Bioimpedance-guided fluid management in maintenance hemodialysis: a pilot randomized controlled trial. Am J Kidney Dis 2014; 64:111.</a></li><li><a class="nounderline abstract_t">Sommerer C, Felten P, Toernig J, et al. Bioimpedance analysis is not superior to clinical assessment in determining hydration status: A prospective randomized-controlled trial in a Western dialysis population. Hemodial Int 2021.</a></li><li><a class="nounderline abstract_t">Sinha AD, Light RP, Agarwal R. Relative plasma volume monitoring during hemodialysis AIDS the assessment of dry weight. Hypertension 2010; 55:305.</a></li><li><a class="nounderline abstract_t">Rodriguez HJ, Domenici R, Diroll A, Goykhman I. Assessment of dry weight by monitoring changes in blood volume during hemodialysis using Crit-Line. Kidney Int 2005; 68:854.</a></li><li><a class="nounderline abstract_t">Katzarski KS, Nisell J, Randmaa I, et al. A critical evaluation of ultrasound measurement of inferior vena cava diameter in assessing dry weight in normotensive and hypertensive hemodialysis patients. Am J Kidney Dis 1997; 30:459.</a></li><li><a class="nounderline abstract_t">Luik AJ, van Kuijk WH, Spek J, et al. Effects of hypervolemia on interdialytic hemodynamics and blood pressure control in hemodialysis patients. Am J Kidney Dis 1997; 30:466.</a></li><li><a class="nounderline abstract_t">Agarwal R, Bouldin JM, Light RP, Garg A. Inferior vena cava diameter and left atrial diameter measure volume but not dry weight. Clin J Am Soc Nephrol 2011; 6:1066.</a></li><li><a class="nounderline abstract_t">Joffy S, Rosner MH. Natriuretic peptides in ESRD. Am J Kidney Dis 2005; 46:1.</a></li><li><a class="nounderline abstract_t">Agarwal R. B-type natriuretic peptide is not a volume marker among patients on hemodialysis. Nephrol Dial Transplant 2013; 28:3082.</a></li><li><a class="nounderline abstract_t">Jaeger JQ, Mehta RL. Assessment of dry weight in hemodialysis: an overview. J Am Soc Nephrol 1999; 10:392.</a></li><li><a class="nounderline abstract_t">Kraemer M, Rode C, Wizemann V. Detection limit of methods to assess fluid status changes in dialysis patients. Kidney Int 2006; 69:1609.</a></li><li><a class="nounderline abstract_t">Reddan DN, Szczech LA, Hasselblad V, et al. Intradialytic blood volume monitoring in ambulatory hemodialysis patients: a randomized trial. J Am Soc Nephrol 2005; 16:2162.</a></li><li><a class="nounderline abstract_t">Loutradis C, Sarafidis PA, Ekart R, et al. The effect of dry-weight reduction guided by lung ultrasound on ambulatory blood pressure in hemodialysis patients: a randomized controlled trial. Kidney Int 2019; 95:1505.</a></li><li><a class="nounderline abstract_t">Loutradis C, Papadopoulos CE, Sachpekidis V, et al. Lung Ultrasound-Guided Dry Weight Assessment and Echocardiographic Measures in Hypertensive Hemodialysis Patients: A Randomized Controlled Study. Am J Kidney Dis 2020; 75:11.</a></li><li><a class="nounderline abstract_t">Loutradis C, Sarafidis PA, Ekart R, et al. Ambulatory blood pressure changes with lung ultrasound-guided dry-weight reduction in hypertensive hemodialysis patients: 12-month results of a randomized controlled trial. J Hypertens 2021; 39:1444.</a></li><li><a class="nounderline abstract_t">K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45:S1.</a></li><li><a class="nounderline abstract_t">Jindal K, Chan CT, Deziel C, et al. Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol 2006; 17:S1.</a></li><li><a class="nounderline abstract_t">Thomson GE, Waterhouse K, McDonald HP Jr, Friedman EA. Hemodialysis for chronic renal failure. Clinical observations. Arch Intern Med 1967; 120:153.</a></li><li><a class="nounderline abstract_t">Raimann J, Liu L, Tyagi S, et al. A fresh look at dry weight. Hemodial Int 2008; 12:395.</a></li><li><a class="nounderline abstract_t">Agarwal R, Weir MR. Dry-weight: a concept revisited in an effort to avoid medication-directed approaches for blood pressure control in hemodialysis patients. Clin J Am Soc Nephrol 2010; 5:1255.</a></li><li><a class="nounderline abstract_t">Mailloux LU. The overlooked role of salt restriction in dialysis patients. Semin Dial 2000; 13:150.</a></li><li><a class="nounderline abstract_t">Ahmad S. Dietary sodium restriction for hypertension in dialysis patients. Semin Dial 2004; 17:284.</a></li><li><a class="nounderline abstract_t">Tattersall J, Martin-Malo A, Pedrini L, et al. EBPG guideline on dialysis strategies. Nephrol Dial Transplant 2007; 22 Suppl 2:ii5.</a></li><li><a class="nounderline abstract_t">Chazot C, Charra B, Laurent G, et al. Interdialysis blood pressure control by long haemodialysis sessions. Nephrol Dial Transplant 1995; 10:831.</a></li><li><a class="nounderline abstract_t">McGregor DO, Buttimore AL, Nicholls MG, Lynn KL. Ambulatory blood pressure monitoring in patients receiving long, slow home haemodialysis. Nephrol Dial Transplant 1999; 14:2676.</a></li><li><a class="nounderline abstract_t">Covic A, Goldsmith DJ, Venning MC, Ackrill P. Long-hours home haemodialysis--the best renal replacement therapy method? QJM 1999; 92:251.</a></li><li><a class="nounderline abstract_t">Agarwal R. Systolic hypertension in hemodialysis patients. Semin Dial 2003; 16:208.</a></li><li><a class="nounderline abstract_t">Santos SF, Peixoto AJ. Revisiting the dialysate sodium prescription as a tool for better blood pressure and interdialytic weight gain management in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3:522.</a></li><li><a class="nounderline abstract_t">Thein H, Haloob I, Marshall MR. Associations of a facility level decrease in dialysate sodium concentration with blood pressure and interdialytic weight gain. Nephrol Dial Transplant 2007; 22:2630.</a></li><li><a class="nounderline abstract_t">Basile C, Pisano A, Lisi P, et al. High versus low dialysate sodium concentration in chronic haemodialysis patients: a systematic review of 23 studies. Nephrol Dial Transplant 2016; 31:548.</a></li><li><a class="nounderline abstract_t">Flanigan MJ, Khairullah QT, Lim VS. Dialysate sodium delivery can alter chronic blood pressure management. Am J Kidney Dis 1997; 29:383.</a></li><li><a class="nounderline abstract_t">Krautzig S, Janssen U, Koch KM, et al. Dietary salt restriction and reduction of dialysate sodium to control hypertension in maintenance haemodialysis patients. Nephrol Dial Transplant 1998; 13:552.</a></li><li><a class="nounderline abstract_t">London GM, Marchais SJ, Guerin AP, et al. Salt and water retention and calcium blockade in uremia. Circulation 1990; 82:105.</a></li><li><a class="nounderline abstract_t">Mugendi GA, Mutua FM, Natale P, et al. Calcium channel blockers for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev 2020; 10:CD011064.</a></li><li><a class="nounderline abstract_t">Tepel M, Hopfenmueller W, Scholze A, et al. Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrol Dial Transplant 2008; 23:3605.</a></li><li><a class="nounderline abstract_t">Tai DJ, Lim TW, James MT, et al. Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis. Clin J Am Soc Nephrol 2010; 5:623.</a></li><li><a class="nounderline abstract_t">Iseki K, Arima H, Kohagura K, et al. Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial. Nephrol Dial Transplant 2013; 28:1579.</a></li><li><a class="nounderline abstract_t">Ruggenenti P, Podestà MA, Trillini M, et al. Ramipril and Cardiovascular Outcomes in Patients on Maintenance Hemodialysis: The ARCADIA Multicenter Randomized Controlled Trial. Clin J Am Soc Nephrol 2021; 16:575.</a></li><li><a class="nounderline abstract_t">Hörl MP, Hörl WH. Drug therapy for hypertension in hemodialysis patients. Semin Dial 2004; 17:288.</a></li><li><a class="nounderline abstract_t">Ross EA, Pittman TB, Koo LC. Strategy for the treatment of noncompliant hypertensive hemodialysis patients. Int J Artif Organs 2002; 25:1061.</a></li><li><a class="nounderline abstract_t">Charytan DM, Himmelfarb J, Ikizler TA, et al. Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. Kidney Int 2019; 95:973.</a></li><li><a class="nounderline abstract_t">Walsh M, Manns B, Garg AX, et al. The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial. Clin J Am Soc Nephrol 2015; 10:1602.</a></li><li><a class="nounderline abstract_t">Quach K, Lvtvyn L, Baigent C, et al. The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis. Am J Kidney Dis 2016; 68:591.</a></li><li><a class="nounderline abstract_t">Matsumoto Y, Mori Y, Kageyama S, et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol 2014; 63:528.</a></li><li><a class="nounderline abstract_t">Lin C, Zhang Q, Zhang H, Lin A. Long-Term Effects of Low-Dose Spironolactone on Chronic Dialysis Patients: A Randomized Placebo-Controlled Study. J Clin Hypertens (Greenwich) 2016; 18:121.</a></li><li><a class="nounderline abstract_t">Scalise F, Sole A, Singh G, et al. Renal denervation in patients with end-stage renal disease and resistant hypertension on long-term haemodialysis. J Hypertens 2020; 38:936.</a></li><li><a class="nounderline abstract_t">Inrig JK, Patel UD, Toto RD, Szczech LA. Association of blood pressure increases during hemodialysis with 2-year mortality in incident hemodialysis patients: a secondary analysis of the Dialysis Morbidity and Mortality Wave 2 Study. Am J Kidney Dis 2009; 54:881.</a></li><li><a class="nounderline abstract_t">Agarwal R, Light RP. Intradialytic hypertension is a marker of volume excess. Nephrol Dial Transplant 2010; 25:3355.</a></li><li><a class="nounderline abstract_t">Van Buren PN, Kim C, Toto R, Inrig JK. Intradialytic hypertension and the association with interdialytic ambulatory blood pressure. Clin J Am Soc Nephrol 2011; 6:1684.</a></li><li><a class="nounderline abstract_t">Chou KJ, Lee PT, Chen CL, et al. Physiological changes during hemodialysis in patients with intradialysis hypertension. Kidney Int 2006; 69:1833.</a></li><li><a class="nounderline abstract_t">Inrig JK, Van Buren P, Kim C, et al. Intradialytic hypertension and its association with endothelial cell dysfunction. Clin J Am Soc Nephrol 2011; 6:2016.</a></li><li><a class="nounderline abstract_t">Inrig JK, Molina C, D'Silva K, et al. Effect of low versus high dialysate sodium concentration on blood pressure and endothelial-derived vasoregulators during hemodialysis: a randomized crossover study. Am J Kidney Dis 2015; 65:464.</a></li></ol></div><div id="topicVersionRevision">Topic 1848 Version 45.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9820438" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hypertension in the ESRD patient: pathophysiology, therapy, outcomes, and future directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9820438" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Hypertension in the ESRD patient: pathophysiology, therapy, outcomes, and future directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9261026" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Report from the 1995 Core Indicators for Peritoneal Dialysis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10070914" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Factors associated with inadequate blood pressure control in hypertensive hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12967694" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24700870" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Assessment and management of hypertension in patients on dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3393741" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Genesis and control of hypertension in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10676725" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Interdialytic weight gain, compliance with dialysis regimen, and age are independent predictors of blood pressure in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17942773" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Home blood pressures are of greater prognostic value than hemodialysis unit recordings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20083728" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Blood pressure and mortality among hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10070915" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9690224" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : "U" curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19027213" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Blood pressure and mortality risk on peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11239017" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Controversy on optimal blood pressure on haemodialysis: normotensive blood pressure values are essential for survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16997057" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The epidemiology of systolic blood pressure and death risk in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17634440" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Which targets in clinical practice guidelines are associated with improved survival in a large dialysis organization?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22718187" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Blood pressure levels and mortality risk among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10052491" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hypertension in the haemodialysis population: any relationship to 2-years survival?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15699452" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: the 58th annual fall conference and scientific sessions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16396968" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Changing relationship of blood pressure with mortality over time among hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15899939" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The association between BP and mortality in patients on chronic peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26293842" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Reverse Epidemiology of Blood Pressure in Peritoneal Dialysis Associated with Dynamic Deterioration of Left Ventricular Function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25287404" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Blood pressure and risk of all-cause mortality in advanced chronic kidney disease and hemodialysis: the chronic renal insufficiency cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15086919" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Seasonal modifications in blood pressure are mainly related to interdialytic body weight gain in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25075771" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Increased postdialysis systolic blood pressure is associated with extracellular overhydration in hemodialysis outpatients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7645554" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Hypertension in the hemodialysis population: a survey of 649 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19153263" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8768921" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Role of volume overload in dialysis-refractory hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9247775" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Importance of volume factors in dialysis related hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5781668" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hypertension in end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1614043" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Survival as an index of adequacy of dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10430965" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Treatment of hypertension in dialysis patients by ultrafiltration: role of cardiac dilatation and time factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11228184" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Strict volume control normalizes hypertension in peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12637629" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Can technology solve the clinical problem of 'dry weight'?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16538880" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Volume control associated with better cardiac function in long-term peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1454086" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Sympathetic overactivity in patients with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18160623" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Arterial stiffness and interdialytic weight gain influence ambulatory blood pressure patterns in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25818679" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Aortic Stiffness, Ambulatory Blood Pressure, and Predictors of Response to Antihypertensive Therapy in Hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2185151" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Plasma endothelin levels in hypertension and chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2565518" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Plasma endothelin levels in patients with uraemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2192712" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Endothelin-3 concentrations in human plasma: the increased concentrations in patients undergoing haemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1347093" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8455369" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Hyperparathyroidism, platelet intracellular free calcium and hypertension in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8651246" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Blood pressure reduction after parathyroidectomy for secondary hyperparathyroidism: further evidence implicating calcium homeostasis in blood pressure regulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19471322" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Regulation of blood pressure and cardiovascular function by renalase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32370572" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : 2020 International Society of Hypertension Global Hypertension Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18627569" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Hypertrophy and fibrosis in the cardiomyopathy of uremia--beyond coronary heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26458123" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19515473" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Chronobiology of arterial hypertension in hemodialysis patients: implications for home blood pressure monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15216485" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Blood pressure measurement in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11054355" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Reproducibility of ambulatory blood pressure monitoring in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16518349" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Home blood pressure monitoring improves the diagnosis of hypertension in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17897244" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : How should hypertension be assessed and managed in hemodialysis patients? Home BP, not dialysis unit BP, should be used for managing hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20350928" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Managing hypertension using home blood pressure monitoring among haemodialysis patients--a call to action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24398888" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32800842" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Treating Home Versus Predialysis Blood Pressure Among In-Center Hemodialysis Patients: A Pilot Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17960059" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Location not quantity of blood pressure measurements predicts mortality in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699236" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Pre- and postdialysis blood pressures are imprecise estimates of interdialytic ambulatory blood pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18495949" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Diagnosing hypertension by intradialytic blood pressure recordings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20167684" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Median intradialytic blood pressure can track changes evoked by probing dry-weight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34313682" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Does This Adult Patient Have Hypertension?: The Rational Clinical Examination Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18497371" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Call to action on use and reimbursement for home blood pressure monitoring: executive summary: a joint scientific statement from the American Heart Association, American Society Of Hypertension, and Preventive Cardiovascular Nurses Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15957127" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Home blood pressure monitoring in CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16139119" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Home blood pressure measurement: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9820471" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Hypertension in patients with chronic renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15004266" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Hypertension and cardiovascular risk assessment in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15696450" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Discordance of influence of hypertension on mortality and cardiovascular risk in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19249092" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19273737" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29212839" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : BP in Dialysis: Results of a Pilot Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26228782" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part I - Assessment and Management of Various Cardiovascular Risk Factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12230477" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Approach to fluid management in peritoneal dialysis: a practical algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18057304" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : On the importance of pedal edema in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2239934" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Body fluid spaces and blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8803988" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Clinical assessment of dry weight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19744155" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Can chronic volume overload be recognized and prevented in hemodialysis patients? The pitfalls of the clinical examination in assessing volume status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24583055" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Bioimpedance-guided fluid management in maintenance hemodialysis: a pilot randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33709483" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Bioimpedance analysis is not superior to clinical assessment in determining hydration status: A prospective randomized-controlled trial in a Western dialysis population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20038754" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Relative plasma volume monitoring during hemodialysis AIDS the assessment of dry weight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16014066" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Assessment of dry weight by monitoring changes in blood volume during hemodialysis using Crit-Line.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9328358" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : A critical evaluation of ultrasound measurement of inferior vena cava diameter in assessing dry weight in normotensive and hypertensive hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9328359" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Effects of hypervolemia on interdialytic hemodynamics and blood pressure control in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21330484" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Inferior vena cava diameter and left atrial diameter measure volume but not dry weight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15983951" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Natriuretic peptides in ESRD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23525529" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : B-type natriuretic peptide is not a volume marker among patients on hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10215341" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Assessment of dry weight in hemodialysis: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16501488" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Detection limit of methods to assess fluid status changes in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15930095" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Intradialytic blood volume monitoring in ambulatory hemodialysis patients: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31027889" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : The effect of dry-weight reduction guided by lung ultrasound on ambulatory blood pressure in hemodialysis patients: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31732234" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Lung Ultrasound-Guided Dry Weight Assessment and Echocardiographic Measures in Hypertensive Hemodialysis Patients: A Randomized Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34074973" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Ambulatory blood pressure changes with lung ultrasound-guided dry-weight reduction in hypertensive hemodialysis patients: 12-month results of a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15806502" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16497879" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4952668" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Hemodialysis for chronic renal failure. Clinical observations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19090861" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : A fresh look at dry weight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20507951" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Dry-weight: a concept revisited in an effort to avoid medication-directed approaches for blood pressure control in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10833773" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : The overlooked role of salt restriction in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15250919" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Dietary sodium restriction for hypertension in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17507427" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : EBPG guideline on dialysis strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7566612" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Interdialysis blood pressure control by long haemodialysis sessions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10534511" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Ambulatory blood pressure monitoring in patients receiving long, slow home haemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10615480" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Long-hours home haemodialysis--the best renal replacement therapy method?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12753679" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Systolic hypertension in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18199846" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Revisiting the dialysate sodium prescription as a tool for better blood pressure and interdialytic weight gain management in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17510098" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Associations of a facility level decrease in dialysate sodium concentration with blood pressure and interdialytic weight gain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25843783" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : High versus low dialysate sodium concentration in chronic haemodialysis patients: a systematic review of 23 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9041214" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Dialysate sodium delivery can alter chronic blood pressure management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9550625" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Dietary salt restriction and reduction of dialysate sodium to control hypertension in maintenance haemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2364508" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Salt and water retention and calcium blockade in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33000470" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Calcium channel blockers for people with chronic kidney disease requiring dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18511605" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20133488" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23355629" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33782036" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Ramipril and Cardiovascular Outcomes in Patients on Maintenance Hemodialysis: The ARCADIA Multicenter Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15250920" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Drug therapy for hypertension in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12487393" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Strategy for the treatment of noncompliant hypertensive hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30473139" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26138259" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27265777" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24184249" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26224543" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Long-Term Effects of Low-Dose Spironolactone on Chronic Dialysis Patients: A Randomized Placebo-Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31990900" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Renal denervation in patients with end-stage renal disease and resistant hypertension on long-term haemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19643520" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Association of blood pressure increases during hemodialysis with 2-year mortality in incident hemodialysis patients: a secondary analysis of the Dialysis Morbidity and Mortality Wave 2 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20400448" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Intradialytic hypertension is a marker of volume excess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21734087" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Intradialytic hypertension and the association with interdialytic ambulatory blood pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16691262" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Physiological changes during hemodialysis in patients with intradialysis hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21757643" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Intradialytic hypertension and its association with endothelial cell dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25530107" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Effect of low versus high dialysate sodium concentration on blood pressure and endothelial-derived vasoregulators during hemodialysis: a randomized crossover study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
